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Summary.-Collagen-peptidase activity in extracts ofHeLa cells and human tumours
is inactivated by Razoxane (ICRF-159), cyclophosphamide, 5-fluorouracil, thiotepa,
aprotinin, EDTA and phenanthroline. As this activity, in association with other
enzymes, may contribute to tissue lysis in cancers, chemical intervention may
reduce invasiveness and modify the processes of infiltration and metastasis. Accord-
ingly, some drugs used in therapy or for the prevention of metastasis may produce
their observed effects by a combination of factors including enzyme inhibition.
FOLLOWING study of collagenase en-
zymes with synthetic peptides by Nagai
et al. (1960), introduction of the chromo-
phore substrate p-phenyl-azo-benzyloxy-
carbonyl-pro-leu-gly-pro-D.arginine by
Wunsch and Heidrich (1963) enabled
collagen-peptidase activity, specific for
apolar peptide sequences analogous to
those of the collagen molecule, to be
identified and assayed in mouse and chick
embryo and in human HeLa cells by
Strauch (1967), Strauch andVencelj (1967)
and Strauch et al. (1968). Although
assays of tumour peptidase with Pz-sub-
strate by Keiditsch and Strauch (1970)
corresponded closely with results obtained
by the method of Nagai et al. (1966) using
14C-labelled collagen as substrate, collagen
peptidase and collagenase when isolated
and purified are not identical. A similar
distribution of the enzymes suggesting a
close functional relationship was also
recorded by Robertson and Williams
(1969) in an invasive rat epithelioma where
collagen-peptidase and true collagenolytic
activity were found in corresponding
regions of the tumour periphery.
Langer et al. (1968) and Keiditsch and
Strauch (1968, 1970) found high levels of
collagen peptidase in human tumours, and
in 1972 Strauch showed benign and non-
invasive tumours to be moderately in-
creased, and malignant tumours of both
epithelial and mesenchymal origin to be
much increased compared with tumour-
free tissue. Invading margins of malignant
tumours had high activity, with lower
values in the centre, still higher than sur-
rounding normal tissues. Other workers
have identified neutral collagenase activity
in tumours, corresponding to that des-
cribed by MeCroskery et al. (1975).
Although collagen- and reticulin-con-
taining structures are among the most
persistent of mammalian tissues, growth
of cancers frequently accompanies exten-
sive breakdown of adjacent connective
tissue, which takes the form of swelling
followed by disorganization and dissolu-
tion (Birbeck and Wheatley, 1965;
Hamperl, 1967; Frithiof, 1972). Such
tissue destruction, associated with eleva-
ted levels of hydrolytic enzymes from
neoplastic and host cells of the cancer and
its stroma, is believed to contribute to
infiltration, invasiveness and possibly met-
astasization (Pearse et al., 1961; Sylven,
1961; Cameron, 1966; Latner et al., 1974;
Carter, 1976; Easty and Easty, 1976).
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154 and ICRF-159 (Razoxane) to have
anti-tumour activity apparently related
to their potential chelating properties.
The correlation between collagen-peptidase
activity and malignancy expressed by the
histological classification of the tumour
(Strauch, 1972) suggested that inhibition of
the responsible enzymes might control and
possiblyreduceneoplastic infiltration (Ras-
segna, 1971; Strauch, 1972). Protease
inhibitors restore contact inhibition (Goetz
et al., 1972) and reduce malignant invasion.
Latner et al. (1974) using the protease
inhibitor Trasylol (aprotinin) observed
reduced invasiveness and tumour size.
Boggust (1976) found that some drugs used
in cancer therapy (including ICRF-159)
were inhibitory in human tumour extracts
capable ofhydrolysing collagen and reticu-
lin as well as Pz-substrate. EDTA and
phenanthroline are also inhibitory of
proteolytic or peptidase activity in tu-
mours (Seifter and Gallop, 1962; Werb et
al., 1974; Boggust, 1976).
This paper shows that several drugs
used clinically as cytostatic or cytotoxic
agents inhibit the collagen peptidase of
HeLa cells and human tumours.
MATERIALS AND METHODS
HeLa cells, cultured 4 days at 37°C in
Eagle's minimum medium with 10% calf
serum, 1% glutamine and antibiotics, wAere
harvested during log phase, washedin Ringer's
solution and counted.
For enzyme activity, cells were extracted
30 min at 37°C with veronal-acetate buffer
pH 7-2 (Documenta Geigy, 1962) diluted to
1-6 vols with water (1 ml to 106 cells) and
centrifuged 10 min at 35,000 g. The pellet was
twice dispersed and re-extracted at 37°C, the
combined supernatant being stored at -25°C
before standardization with p-phenyl-azo-
benzyl - oxycarbonyl - pro - leu - gly - pro - D-
arginine.
Tumours from surgery, examined histo-
logically, included adenocarcinomas of colon,
rectum and kidney, squamous carcinomas of
vulva, scirrhous carcinomas of breast, inva-
sive squamous carcinoma ot ear and differ-
entiated squamous carcinoma of finger.
Tumour (0 5 g), free from normal tissue, fat,
necrotic or infected mnaterial, was disinte-
grated by 4 passes at -25°C in the Biotec
X-press, (lispersed in diluted veronal-acetate
buffer, pH 7-2 (1 ml) and centrifuged for
10 min at 5°C and 30,000 g. The residue was
suspended x 4 and re-extracted in 0 5 ml
portions of cold buffer, the combined super-
natants being stored at -25°C. Only a
limited number of assays could be performed
with the extract from each tumour.
For assay, mixtures containing serial
dilutions of cell or tissue extract, or buffer
control (0-25 inl) and buffer (0.5 ml) were pre-
incubated at 37°C for 1 h before adding
substrate solution (0 4 mg/ml in buffer) or
buffer (0 5 ml) with incubation for 15 min.
After adding 0.500 citric acid (2.5 ml) extracts
in ethyl acetate (2 x 2-5 ml) combined and
dried over anhydrous Na2SO4 gave optical
densities at A=320 nm.
For assay of inhibition, mixtures contain-
ing cell or tissue extract (0(25 ml) serial
dilutions of test substance in buffer prepared
with minimal warming or control buffer
(0-25 ml) and buffer (0-25 ml) were set up in
duplicate and preincubated at 37°C for 1 h;
substrate solution in buffer (0.5 ml) was
added to one series and buffer (0 5 ml) tothe
other as controls: all were incubated for
15 min at 37°C and treated as described
above. Inhibition of collagen-peptidase was
calculated from the dilution/optical-density
curve obtained by assay of serially diluted
untreated extracts.
RESULTS
Representative findings are presented as
Go inhibition of collagen-peptidase acti-
vity in HeLa extracts (Table I) and
tumour extracts (Table II) by drugs at
stated concentrations in each complete in-
cubation mixture. Peptidase activities in
OD 320 units are given for comparison of
the extracts and molar concentrations of
drugs producing 5000 inactivation are
computed from the data.
HeLa extracts were generally repro-
ducible in character and activity, but
tumour extracts showed considerable var-
iations in assayable activity, and especi-
ally in their total solutes, which possibly
modified the action and effective concen-
tration of test drugs.
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TABLE I.-Inhibition of HeLa collagen
peptidase by drugs at stated concentra-
tions in each incubation mixture. Pepti-
dase activities for each extract are given
in OD units for comparison together with
computed concentrations of drugs pro-
ducing 50% inhibition.
Razoxane
TABLE II.-Inhibition of tumour collagen
peptidase by drugs at stated concentra-
tions in each incubation mixture. Pepti-
dase activities for each extract are given
in OD units for comparison together with
computed concentrations of drugs pro-
ducing 50% inhibition.
Extract,
OD/320 mg/ml 0-6 0-2 0-06
nm M 2 -24 0 75 0 22
% inhibition
0-031 97*0 75*0 21-0
0-030 91*0 65*0 22 0
0-030 87*0 70-0 22*0
Cyclophosphamide
mg/ml 2'0 0 6 0 2
M 7-66 2-30 0 77
% inhibition
0-054 64*0 46*0 34 0
0*050 61-0 71-0 40*0
0-038 - 69*0 42-0
5-Fluorouracil
mg/ml 2-0 1-0 0-2
M 15-38 7-69 1-54
% inhibition
0-032 70-0 50-0 29-0
0-032 93-0 79-0 39-0
0-031 79-0 57-0 21-5
M for Razoxane
0 50% Extract,
0 inhib. OD/320
rn
0 0*43 0*070
0 0-43 0-137
0 0-48 0 053
0-158
0
0
0 3-0
0 1-15
0 1-15
0
0
0
0
0
7.7
2-7
5-8
mg/ml 0-6 0-2 0-06
M 2-24 0-75 0-22
% inhibition
75-0 59-0 48-0
- 49-0 40-0
- 46-0 36-0
26-0 19-5 6-5
M for
0 50%
0 inhib.
0
0
0
0
0-28
0-78
1-12
2 -24
Cyclophosphamide
mg/ml 2-0 0-6 0-2 0-06 0
M 7-66 2-30 0-77 0-23 0
% inhibition
0-045 91-0 71-0 47-0 15-0 0 0-88
0-040 87-5 13-0 - - 0 1-03
5-Fluorouracil
mg/ml 4-0 2 -0 1-4
M 30-77 15-38 10-77
% inhibition
0-023 - 87-5 75-0
0-029 74-0 56-0
0-026 37-0 24-0
1-0
7-69
9-0
43-0
24-0
0
0
0
0
0
6-15
9-23
Thiotepa
mg/ml 3-0 2-0 1-0 0-3
M 15-87 10-58 5-29 1-59
% inhibition
0 032 - 70-0 22-0
0 030 68-0 - 39-0 22-0
Thiotepa
0
0
0 8-7
0 8-7 0-037
0-021
mg/ml 1- 2 0 4
M 6-35 2-12
% inhibition
96-0
84-0 73 5
0-12 0
0-63 0
- 0 0-95
12-0 0 1-27
Aprotinin
KI units/ml 2000 600 200
% inhibition
0-033 99-0 57-0 0
0-063 74-0 57-0 13-0
0-065 80-0 70-0 17-0
EDTA
mg/ml 200 60 20 6
M 0-68 0-20 0 07 0-02
0/ inhibition
0 033 79 0 69-0 55.0 10-0
0-035 100-0 100-0 91-0 80-0
Aprotinin 0
0
0
0
0-045
KI units/ml 2000 600 2(
% inhibition
; 63 33 0
00 0
0
EDTA
0
0
0 0-06
0 0-02
0-041
0-167
,g/ml 200 60 20 6 0
M 0-68 0-20 0-07 0-02 0
% inhibition
- - 39-0 15-0 0 0-12
50-0 21-0 10-0 - 0 0-68
Phenanthroline
mg/ml 0 6 0-2 0-06
M 3-33 1-11 0-33
% inhibition
0 035 100-0 95-0 70 0
0 035 100 0 58-0 80-0
0-031 71-0 45-0 0
0
0
0
0
0
0-22
0-22
1 -33
Phenanthroline
mg/ml0-2 0-06 0-02 0-006 0
M 1-11 0-33 0.11 0-03 0
% inhibition
0-045 96-0 96-0 - 0 0-030
0-117 94 0 80-0 - - 0 0-08
0-030 94 0 67-0 50-0 23-00 0 0-11
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Excepting aprotinin, for which no
comparison can be expressed in molar
units, decreasing inhibition of tumour
peptidase was observed in the order
phenanthroline, EDTA, Razoxane, cyclo-
phosphamide, thiotepa, 5-FU. With HeLa
extracts, EDTA and 5-FU were rather
more effective than phenanthroline and
thiotepa respectively.
The results show better than 50% in-
activation oftumour collagen peptidase at
concentrations of inhibitor substantially
less than upper levels for therapy cited for
Razoxane (ICRF-159) (Wasserman et al.
1973) and for cyclophosphamide, aprotinin
and EDTA (Martindale, 1972). 5-FU
produced variable levels of inhibition and
not all tumour extracts were inhibited.
Phenanthroline, a potent inhibitor of
collagen peptidase, produces a neuro-
muscular reaction in mice at levels above
5 ,ug/g (Peters, 1975).
No inhibition was seen with N-acetyl-
glucosamine, bleomycin, colchicine, cy-
tarabine, dactinomycin, daunorubicin,
iodoacetamide, levamisole, methotrex-
ate, phosphocreatine, vinblastine or vin-
cristine.
No overall biochemically acceptable
reaction mechanism can be proposed,
as the lack of specificity in the inhibitory
compounds indicates that the biological
situation is complex and may involve
more than the blockade ofa single enzyme-
substrate reaction. As incubation of test
substances in buffer showed no significant
change of pH, reduced hydrolysis of sub-
strate is not due to enzyme denaturation
or to the effect of a less favourable pH
upon activity.
DISCUSSION
Certain cytotoxic drugs have beenshown
to inactivate the collagen peptidase from
HeLa cells in culture as well as in extracts
of spontaneous human tumours. In addi-
tion to malignant cells, tumours may con-
tain non-neoplastic host cells infiltrated
into the stroma, including leucocytes,
macrophages and fibroblasts. Although
such cells have been reported, by various
authors, to contain collagenolytic enzymes,
no information is available specifically
about their collagen-peptidase activity or
its inhibition. Accordingly the overall
contribution ofsuch drugs to the control of
tissue lysis around tumours has yet to be
assessed in full.
The role of collagen peptidase in rela-
tion to intact macromolecules of tissue
structuresintheenvironmentoftumours is
consideredto involve the continuation and
extension of lysis begun by the action of
true proteases with which they are closely
associated.
The relevance of collagen-protease and
collagen-peptidase activity to invasive-
ness and metastasization is related to the
weakening of, or creation of defects in,
physical barriers to tumour growth. Nat-
ural substrates include components and
degraded forms of glycoprotein or muco-
polysaccharide such as are found in
collagen, reticulin, fibrin and the ground
substance in matrix of basement mem-
brane, connective tissue, intercellular ce-
ment, or in the perithelial structure of the
micro-vascular system round the tumour.
Lysis of these materials may release cells
from the tumour mass, open up pathways
for invasion into surrounding areas, or
allow passage of cancer cells into the
lumen of adjacent lymphatic or blood
capillaries for transport to metastatic
sites.
Inhibitors of collagenase and collagen-
peptidase activity modifytheenvironment
of cancers by reducing the hydrolysis
of substances which prevent tumour-cell
release and movement. By constraining
the tumour within the surrounding
stroma, blockade of expansive and in-
vasive growth may produce a state like
basal-cell carcinomas, which form an
enveloping capsule usually staining for
reticulin. Such tumours are potentially
invasive but, if unable to lyse their cap-
sule, remain benign and undergo matura-
tion and keratinization. By reducing lysis
of reticulin-like components in capillary
perithelium, enzyme inhibition may con-
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tribute to vascular integrity, reduce the
incidence of haemorrhage round tumours,
and reduce the number of malignant cells
penetrating the circulatory system, as
reported for ICRF-159 in a metastasizing
mouse tumour by Salsbury et al. (1970).
A synergistic combination of the enzyme-
inhibitors ICRF-159 and o-phenanthro-
line markedly protected tumour-bearing
micefrommetastasization (Boggust, 1976).
Taken in conjunction with the cyto-
static and cytotoxic effect of these drugs
on the proliferating cells of the tumour
and its stroma, it is possible that observed
remissions in tumour viability may be
due to the interaction of several factors
including those outlined above.
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